Loading company…
Pleco Therapeutics develops therapies intended to improve cancer treatment outcomes.
Founded in 2018 and based in Nijmegen, Pleco Therapeutics is a clinical-stage biopharmaceutical company developing Plecoid therapies intended to increase the effectiveness of cancer treatments. Its candidates include PTX-061, PTX-062, and PTX-081. In September 2022, it received EUR 5 million in grant funding as part of a larger EUR 17.30 million Series A and grant round.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in